Shire resubmits methylphenidate patch
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Shire and partner Noven's response to an April 2003 "not approvable" letter for their methylphenidate transdermal patch for attention deficit hyperactivity disorder has been accepted by FDA, the firms announce July 26. The NDA was resubmitted June 28. Included in the submission are two additional studies: a 270-patient Phase III trial and a 79-patient Phase II trial. Both studies were seven weeks and enrolled children between six and 12 years of age. The sponsors are seeking an indication for treatment of that age group in the new NDA. The product, formerly MethyPatch, would be the first methylphenidate product available in patch form...
You may also be interested in...
Shire Daytrana "complete response"
Shire development partner Noven completes a Class 1 "complete response" to FDA's December 2005 "approvable" letter for the firms' attention deficit hyperactivity disorder patch Daytrana (methylphenidate transdermal system), Noven says March 6. If accepted for review, Daytrana could be approved in May. Noven began inventory production of Daytrana in mid-December in anticipation of a mid-year launch. Daytrana had been deemed "not approvable" by FDA in April 2003; a response to that letter was submitted in June 2005 (1Pharmaceutical Approvals Monthly August 2005, In Brief)...
Shire/Noven Daytrana data
Shire and Noven's Phase II study of ADHD methylphenidate transdermal system Daytrana, presented at the American Academy of Child & Adolescent Psychiatry in Toronto Oct. 20 & 21, shows a statistically significant improvement over placebo after 12 hours (p<0.001). Similar results to the 79-patient Phase II "classroom study" were seen in the 270-patient Phase III "naturalistic" trial measuring "overall symptoms," also reported at AACAP. The trials are included in Shire's June 28 resubmission for use in children ages six to 12 (1Pharmaceutical Approvals Monthly August 2005, In Brief). A Dec. 2 review is planned by FDA's Psychopharmacologic Drugs Advisory Committee...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.